| Cardiovascular Risk Management |
1 |
1 |
| Food and Drug Administration (FDA) |
0 |
0.9 |
| Thromboembolism |
0 |
0.81 |
| Epidemiology |
0 |
0.54 |
| Oregon |
0 |
0.54 |
| Venous Thromboembolism (VTE) |
0 |
0.5 |
| Rheumatoid Arthritis |
0 |
0.9 |
| Arthritis |
0 |
0.27 |
| Biologic Therapy |
0 |
0.24 |
| Revenue and Practice Management |
0 |
0.24 |
| Biosimilars |
0 |
0.14 |
| Cancer |
0 |
0.14 |
| Cardiovascular Imaging |
0 |
0.14 |
| Clinical Research |
0 |
0.14 |
| Colorado |
0 |
0.14 |
| Echocardiography |
0 |
0.14 |
| Healthcare and Medical Technology |
0 |
0.14 |
| Herpes Zoster |
0 |
0.14 |
| Hospital |
0 |
0.14 |
| Insurance |
0 |
0.14 |
| Medicare |
0 |
0.14 |
| Psoriasis |
0 |
0.14 |